SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/135153"
 

Search: onr:"swepub:oai:gup.ub.gu.se/135153" > Differential effect...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Edén, Arvid,1975Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine,University of Gothenburg (author)

Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • Mary Ann Liebert Inc,2010

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/135153
  • https://gup.ub.gu.se/publication/135153URI
  • https://doi.org/10.1089/aid.2009.0177DOI
  • https://lup.lub.lu.se/record/1618079URI
  • https://research.chalmers.se/publication/135153URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:120417682URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Initial viral decay rate may be useful when comparing the relative potency of antiretroviral regimens. Two hundred twenty-seven ART-naïve patients were randomized to receive efavirenz (EFV) (n = 74), lopinavir/ritonavir (LPV/r) (n = 77), or atazanavir/ritonavir (ATV/r) (n = 79) in combination with two NRTIs. The most frequently used NRTI combinations in the EFV and ATV/r groups were the nonthymidine analogues tenofovir and emtricitabine or lamivudine (70% and 68%, respectively) and, in the LPV/r group, lamivudine and the thymidine analogue zidovudine (89%). HIV-1 RNA was monitored during the first 28 days after treatment initiation. Phase 1 and 2 decay rate was estimated in a subset of 157 patients by RNA decrease from days 0 to 7, and days 14 to 28. One-way ANOVA and subsequent Tukey's post hoc tests were used for groupwise comparisons. Mean (95% CI) HIV-1 RNA reductions from days 0 to 28 were 2.59 (2.45-2.73), 2.42 (2.27-2.57), and 2.13 (2.01-2.25) log(10) copies/ml for the EFV-, LPV/r-, and ATV/r-based treatment groups, respectively, with a significantly larger decrease in the EFV-based group at all time points compared with ATV/r (p < 0.0001), and with LPV/r at days 7-21 (p < 0.0001-0.03). LPV/r gave a greater RNA decrease compared with ATV/r from day 14 (p = 0.02). Phase 1 decay rate was significantly higher in the EFV group compared with LPV/r (p = 0.003) or ATV/r (p < 0.0001). No difference was found in phase 2 decrease. EFV-based treatment gave a more rapid decline in HIV-1 RNA than did either of the boosted protease inhibitor-based regimens. The observed differences may reflect different inherent regimen potencies.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Andersson, Lars-Magnus,1968Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine,University of Gothenburg(Swepub:gu)xalarh (author)
  • Andersson, Orjan (author)
  • Flamholc, LeoLund University,Lunds universitet,Enheten för infektionssjukdomar,Forskargrupper vid Lunds universitet,Infectious Diseases Research Unit,Lund University Research Groups,Skånes universitetssjukhus (SUS),Skåne University Hospital(Swepub:lu)inf-lfl (author)
  • Josephson, FilipKarolinska universitetssjukhuset,Karolinska University Hospital (author)
  • Nilsson, Staffan,1956Gothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper, matematisk statistik,Department of Mathematical Sciences, Mathematical Statistics,Chalmers tekniska högskola,Chalmers University of Technology,University of Gothenburg(Swepub:cth)staffan (author)
  • Ormaasen, VidarOslo universitetssykehus,Oslo University Hospital (author)
  • Svedhem, VeronicaKarolinska Institutet (author)
  • Säll, ChristerSödra Älvsborgs Sjukhus (SÄS),Södra Älvsborg Hospital (SÄS) (author)
  • Sönnerborg, AndersKarolinska Institutet (author)
  • Tunbäck, Petra,1965Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för dermatologi och venereologi,Institute of Clinical Sciences, Department of Dermatology and Venereology,University of Gothenburg(Swepub:gu)xtunpe (author)
  • Gisslén, Magnus,1962Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine,University of Gothenburg(Swepub:gu)xgissm (author)
  • Göteborgs universitetInstitutionen för biomedicin, avdelningen för infektionssjukdomar (creator_code:org_t)

Related titles

  • In:AIDS research and human retroviruses: Mary Ann Liebert Inc26:5, s. 533-401931-84050889-2229

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view